Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations

Annals of Surgical Oncology

Volumn 9, Issue 10, 2002, Pages 941-943

  Roukos, Dimitrios H ^a,b   Agnanti, Niki J ^a   Paraskevaidis, Evangelos ^a   Kappas, Angelos M ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; EARLY DIAGNOSIS; ECHOGRAPHY; EDITORIAL; FAMILIAL CANCER; FAMILY HISTORY; FOLLOW UP; GENE MUTATION; GENETIC COUNSELING; HETEROZYGOTE; HUMAN; LAPAROSCOPIC SURGERY; MASTECTOMY; MEDICAL DECISION MAKING; OVARIECTOMY; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PROPHYLAXIS; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; DECISION MAKING; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASTECTOMY; OVARIAN NEOPLASMS; OVARIECTOMY;

EID: 0036894814     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2002.10.010     Document Type: Editorial

References (26)

1. Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes (editorial). Ann Surg Oncol 2002;9:607-9.
2. Hedenfalk I, Duggan D, Chen Y. et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-48.
3. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
4. Jazaeri A, Yee C, Sotiriou C, Brantley K, Boyd J, Liu E. Gene expression profiles of BRCA1-linked, and sporadic ovarian cancers? J Natl Cancer Inst 2002;94:990-1000.
5. Hedenfalk I. Gene expression profiling of hereditary and sporadic ovarian cancers reveals unique BRCA1 and BRCA2 signatures. J Natl Cancer Inst 2002;94:960-1.
6. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
7. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCAI and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
8. Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241-7.
9. Hopper JL, Southey MC, Dite GS, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741-7.
10. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
11. Satagopan JM, Offit K, Foulkes W, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001;10:467-73.
12. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
13. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000;83:1301-8.
14. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72.
15. Thorlacius S, Struewing JP, Hartge, P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352:1337-9.
16. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
17. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-64.
18. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations. N Engl J Med 1997;336:1465-71. [Erratum, N Engl J Med 1997;337:434].
19. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998;16:979-85.
20. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-9.
21. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oo-phorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
22. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
23. Gabriel SE, Woods JE, O'Fallon WM, Beard CM, Kurland LT, Melton LJ III. Complications leading to surgery after breast implantation. N Engl J Med 1997;336:677-82.
24. Frost MH, Schaid DJ, Sellers TA, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 2000;284:319-24.
25. Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: Psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 2001;10:231-41.
26. Kuhl CK, Schmutzler RK, Leutner C, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results. Radiology 2000;215:267-79.